Second EMA Public Hearing To Focus On Quinolone, Fluoroquinolone Side Effects
Executive Summary
The European Medicines Agency wants to hear testimonies from the public about serious side effects that have been observed in patients treated with quinolone- and fluoroquinolone-containing medicinal products.
You may also be interested in...
Huge Interest In EMA's Public Hearing On Side-Effects Of Quinolones, Fluoroquinolones
The European Medicines Agency has chosen 23 speakers from 55 requests made by people interested in sharing their experiences with the use of these widely-prescribed antibiotics.
Fluoroquinolones Get New Safety Labeling, But Not A REMS
Risk of disabling, potentially permanent serious side effects that can occur together will be added to Cipro, Levaquin labels along with limitation against use for some self-limiting conditions unless there are no alternative treatments.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.